跳到正文
原文
MedPage Today·· 16 天前精选AI 评分76

达洛鲁胺在高风险前列腺癌患者中显著提高无转移生存率

Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer

AI 导读

达洛鲁胺联合雄激素剥夺疗法和局部放射治疗显著提高了高风险前列腺癌患者的无转移生存率,4年生存率为95%,比安慰剂组的88%提高了58%。

推荐理由

详细报道了III期临床试验结果,显示darolutamide显著提高高风险前列腺癌患者的无转移生存率。

正文

— Phase III DASL-HiCaP trial showed a 58% reduction in the risk of metastasis or death

by Gregory Laub, Senior Director, Video, MedPage Today

November 4, 2026 • 3 min read

Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to findings from the phase III DASL-HiCaP trial presented at the European Society for Medical Oncology congress. At 4 years, the metastasis-free survival rate was 95% with darolutamide versus 88% with placebo.

In this exclusive MedPage Today video, investigator Tamim Niazi, MDCM, of McGill University in Montreal, discusses the findings, including which patients may benefit most from treatment intensification, the safety results, and why he considers the data practice-changing.

Following is a transcript of his remarks:

So DASL-HiCaP, it was a phase III randomized trial assessing the role of the additional darolutamide to 24 months of androgen deprivation therapy plus a locoregional radiation therapy for patients who are at DASL very high risk, so specifically selected patients who are very high risk based on DASL criteria. We'll talk about this in a minute or two.

But what this study actually showed for these patients who are at a very high risk of recurrence and relapse is that adding darolutamide increased the metastasis-free survival by conventional imaging. It's important, it's not by PSMA [prostate-specific membrane antigen], it's by conventional imaging at 4 years, from 88% in the placebo arm to 95% in the darolutamide arm, with a hazard ratio of 0.48. That is a 58% risk reduction in favor of darolutamide.

So how we define very high risk in DASL-HiCaP is not the usual high risk and not the same thing as STAMPEDE very high risk.

For patients who had prostate in place for primary radiation therapy, the very high risk was defined as either grade group 5, Gleason 9-10, or pelvic lymph node disease. Any of those would've made participants eligible. And for participants who had a grade group 4, meaning Gleason 8, they had to have an additional risk factor, either a clinical T2b or higher, a PSA [prostate-specific antigen] more than 20, or radiological T3a or higher.

On the other hand, for patients who had salvage radiation therapy after radical prostatectomy, those patients had to have their PSA either persistent after surgery, meaning having not gone to zero or rising within 12 months to a 0.1 or higher. They would've been eligible to participate as long as they met the eligibility criteria, either a grade group 5 with a Gleason 9 or 10 of course, or pathological or clinical pelvic lymph node positive. Similar to primary radiation therapy, patients in salvage were also eligible if they had grade group 4, and were also eligible if they had an additional risk of pathological T3a or higher.

But to us, it is a more higher-risk patient population compared to other studies, for example, ENZARAD, but not STAMPEDE.

Both groups received the contemporary doses of radiation therapy and hormonal therapy, higher doses of 78 Gy and higher in primary setting, 64 Gy and higher in salvage setting. And of course the pelvic radiation therapy was mandated in the study.

So the standard treatment was given very well to the contemporary stage, and then it was for darolutamide to show an improvement. So it did. It decreased the risk of metastasis by 58%. To me, I think it is practice-changing and it definitely defines a new path for patients who are at a very high risk of recurrence.

Not only did it significantly improve metastasis-free survival, the adverse events were pretty similar between the two groups. Specifically, there was no additional cardiovascular toxicity by adding darolutamide. It was almost identical between the two groups. And furthermore, the addition of darolutamide to locoregional radiation therapy did not cause new emergent toxicity when it comes into a combination of treatment in this investigation.

来源:MedPage Today · medpagetoday.com